Adam Kleger, Head of Client Solutions
Inspired by the FDA’s Patient Focused Drug Development (PFDD) guidance, inVibe Labs launched TrialPulse in early 2021. Given inVibe’s previous success with innovative voice market research solutions for commercial pharmaceutical brands, the team saw a unique and compelling opportunity to apply an analogous approach to drug development.
Built on the backbone of inVibe’s Automated Voice Response (AVR) platform, TrialPulse leverages a library of “Insight Templates” that are specifically aligned to six important areas in the drug development process: (1) Patient Experience; (2) Burden of Disease; (3) Unmet Needs; (4) Trial Design; (5) Recruitment Asset Evaluation; and (6) Retention Optimization.
For a typical TrialPulse study, inVibe recruits 20 patients and/or caregivers in a specific disease state, provides them with the relevant stimuli (e.g., protocol summaries, e-consent forms, patient recruitment brochures, etc.), then prompts them to provide specific thoughts/feedback via a proprietary AVR interview. The entire process takes less than 20 minutes and can be done on the participants’ own time via their smartphone without the need to schedule an appointment or download an app. All they need to do is click a button that triggers a phone call, listen to pre-recorded questions, and share their thoughts by simply speaking.
All of the data is collected and analyzed in an interactive, searchable, filterable online portal—the patient voice recordings can easily be shared with other team members, and the rich data repository can continue to build over time, providing stakeholders with access to voice recordings, written transcripts, and historical reports and executive summaries created by inVibe analysts.
By providing unprecedented transparency into the hearts and minds of patients, TrialPulse helps sponsors save time and money along the clinical milestones, ultimately resulting in better, more patient-centric therapeutics.